Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Spero Therapeutics (SPRO) Interest & Investment Income (2017 - 2025)

Spero Therapeutics (SPRO) has disclosed Interest & Investment Income for 9 consecutive years, with $532000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest & Investment Income fell 54.99% year-over-year to $532000.0, compared with a TTM value of $3.2 million through Sep 2025, down 33.38%, and an annual FY2024 reading of $4.7 million, up 20.27% over the prior year.
  • Interest & Investment Income was $532000.0 for Q3 2025 at Spero Therapeutics, down from $740000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.3 million in Q1 2024 and bottomed at $72000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $645263.2, with a median of $740000.0 recorded in 2025.
  • The sharpest move saw Interest & Investment Income plummeted 58.65% in 2021, then surged 1237.5% in 2023.
  • Year by year, Interest & Investment Income stood at $76000.0 in 2021, then skyrocketed by 840.79% to $715000.0 in 2022, then soared by 45.73% to $1.0 million in 2023, then dropped by 1.34% to $1.0 million in 2024, then plummeted by 48.25% to $532000.0 in 2025.
  • Business Quant data shows Interest & Investment Income for SPRO at $532000.0 in Q3 2025, $740000.0 in Q2 2025, and $864000.0 in Q1 2025.